Could a transplant drug tame stubborn low platelets in antiphospholipid syndrome?
NCT ID NCT06722586
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether sirolimus (rapamycin), an immune-suppressing drug, can safely raise platelet counts in people with antiphospholipid antibodies and persistent low platelets. Participants are randomly assigned to receive sirolimus or a placebo for six months, and those who do not respond may receive sirolimus for an additional three months. The main goal is to see if sirolimus leads to a meaningful increase in platelet levels compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sirolimus (rapamycin)
What this could lead to
If it works, sirolimus could offer a new, steroid-sparing option to manage low platelet counts in people with antiphospholipid antibodies.
What could go wrong
This is a Phase 4 trial with 84 participants. Sirolimus may not improve platelet counts more than placebo, and side effects like mouth sores, infections, or high cholesterol are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPAENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chao-Yang Hospital
RECRUITINGBeijing, 100020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Shijitan Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Third Hospital
RECRUITINGBeijing, 100083, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
People's Hospital of Xinjiang Uygur Autonomous Region
RECRUITINGÜrümqi, Xinjiang, 830001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shangdong, 250012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Renji Hospital
RECRUITINGShanghai, 200001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The 1st Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325015, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••